+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020

  • ID: 5137275
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 72 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CCH Pharmaceuticals ApS
  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Mind Medicine Inc
  • NeuroPharm Inc
  • MORE
Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2020, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CCH Pharmaceuticals ApS
  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Mind Medicine Inc
  • NeuroPharm Inc
  • MORE
  • Introduction
  • Report Coverage
  • Cluster Headache Syndrome (Cluster Headache) - Overview
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
  • CCH Pharmaceuticals ApS
  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Mind Medicine Inc
  • NeuroPharm Inc
  • TrioxBio Inc
  • Winston Pharmaceuticals Inc
  • Zosano Pharma Corp
  • Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
  • CLE-500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galcanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ketamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
  • Cluster Headache Syndrome (Cluster Headache) - Discontinued Products
  • Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 08, 2020: Phase 2 clinical trial of LSD for "Suicide Headaches" begins treating patients
  • Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality
  • Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
  • Jun 05, 2019: FDA approves first drug for episodic cluster headaches
  • May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio
  • Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults
  • Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
  • May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
  • Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by CCH Pharmaceuticals ApS, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Mind Medicine Inc, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by NeuroPharm Inc, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Winston Pharmaceuticals Inc, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Zosano Pharma Corp, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H2 2020
  • Cluster Headache Syndrome (Cluster Headache) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • CCH Pharmaceuticals ApS
  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Mind Medicine Inc
  • NeuroPharm Inc
  • TrioxBio Inc
  • Winston Pharmaceuticals Inc
  • Zosano Pharma Corp
Note: Product cover images may vary from those shown
Adroll
adroll